This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Iofetamine I-123
- DrugBank Accession Number
- DB09480
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Iofetamine I-123 (DB09480)
- Weight
- Average: 299.189
Monoisotopic: 299.049522528 - Chemical Formula
- C12H18IN
- Synonyms
- Iodine iofetamine (123I)
- Iofetamine (123 I)
- Iofetamine (123I)
- Iofetamine I 123
- Iofetamine, I-123
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Abaloparatide. Acebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Iofetamine I-123. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Iofetamine I-123. Acemetacin The risk or severity of hypertension can be increased when Iofetamine I-123 is combined with Acemetacin. Acetazolamide Acetazolamide may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level. Acetophenazine Acetophenazine may decrease the stimulatory activities of Iofetamine I-123. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Iofetamine I-123. Aclidinium The risk or severity of Tachycardia can be increased when Aclidinium is combined with Iofetamine I-123. Acrivastine Iofetamine I-123 may decrease the sedative and stimulatory activities of Acrivastine. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Iofetamine I-123. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Iofetamine hydrochloride I-123 R5O1XB5L3M 85068-76-4 AFLDFEASYWNJGX-FOHXBPHZSA-N
Categories
- ATC Codes
- V09AB01 — Iodine iofetamine (123i)
- Drug Categories
- Agents producing tachycardia
- Agents that produce hypertension
- Amines
- Amphetamines
- Central Nervous System
- Compounds used in a research, industrial, or household setting
- Diagnostic Radiopharmaceuticals
- Diagnostic Uses of Chemicals
- Ethylamines
- Indicators and Reagents
- Iodine (123I) Compounds
- Laboratory Chemicals
- Phenethylamines
- Radiopharmaceuticals
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Sympathomimetics
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Phenethylamines
- Direct Parent
- Amphetamines and derivatives
- Alternative Parents
- Phenylpropanes / Iodobenzenes / Aralkylamines / Aryl iodides / Dialkylamines / Organopnictogen compounds / Organoiodides / Hydrocarbon derivatives
- Substituents
- Amine / Amphetamine or derivatives / Aralkylamine / Aromatic homomonocyclic compound / Aryl halide / Aryl iodide / Halobenzene / Hydrocarbon derivative / Iodobenzene / Organic nitrogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LV23B78IJC
- CAS number
- 75917-92-9
- InChI Key
- ISEHJSHTIVKELA-DCWJVSPSSA-N
- InChI
- InChI=1S/C12H18IN/c1-9(2)14-10(3)8-11-4-6-12(13)7-5-11/h4-7,9-10,14H,8H2,1-3H3/i13-4
- IUPAC Name
- {1-[4-(¹²³I)iodophenyl]propan-2-yl}(propan-2-yl)amine
- SMILES
- CC(C)NC(C)CC1=CC=C([123I])C=C1
References
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00511 mg/mL ALOGPS logP 3.58 ALOGPS logP 3.94 ChemAxon logS -4.8 ALOGPS pKa (Strongest Basic) 10.35 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 12.03 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 71.01 m3·mol-1 ChemAxon Polarizability 27.78 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at November 30, 2015 19:10 / Updated at June 12, 2020 16:52